Autophagy is required for the therapeutic effects of the NAD+ precursor nicotinamide in obesity-related heart failure with preserved ejection fraction
Mahmoud Abdellatif(Inserm), Simon Sedej(Medical University of Graz), Abhinav Diwan(Washington University in St. Louis), Francisco Vasques‐Nóvoa(Universidade do Porto), Ruli Feng(Medical University of Graz), Jihoon Nah(Rutgers, The State University of New Jersey), Eun‐Ah Sung(Virginia Commonwealth University), Wolfgang A. Linke(University Hospital Münster), Viktoria Trummer-Herbst(Medical University of Graz), Guido Kroemer(Institut Universitaire de France), Andreas Prokesch(Medical University of Graz), Sylvère Durand(Inserm), Junichi Sadoshima(Rutgers, The State University of New Jersey), João Pedro Ferreira(Inserm), Fanny Aprahamian(Délégation Paris 5), Moydul Islam(Washington University in St. Louis), Franziska Koser(University Hospital Münster)
Cited by 24
Related Papers
Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors
|Science|2017|5.4k
Empagliflozin in Heart Failure with a Preserved Ejection Fraction
|New England Journal of Medicine|2021|4.6k
Classification of cell death: recommendations of the Nomenclature Committee on Cell Death 2009
|Cell Death and Differentiation|2008|3.3k
Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)<sup>1</sup>
|Autophagy|2021|2.7k
The molecular machinery of regulated cell death
|Cell Research|2019|2.5k